Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $75M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Frazier Li... | frazierls.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.12.2022 | Series B | $75M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 15.12.2022 | Alpha-9 Theranostics Raises $75M in Series B Financing | Alpha-9 Theranostics, a Boston, MA- and Vancouver, Canada-based clinical stage radiopharmaceutical c... | finsmes.co... |
| - | Alpha9 Theranostics | “Alpha9” | fastfounde... |